A 72-year-old man presents to the emergency department with severe chest pain and progressive shortness of breath for 4 hours. The pain is sudden in onset, substernal, crushing, radiates to the left arm and jaw, and is associated with diaphoresis, nausea, and vomiting. He has a history of hypertension, type 2 diabetes mellitus, ischemic heart disease, and heart failure with reduced ejection fraction, and is a current smoker with a 40-pack-year history. On examination, he appears pale, anxious, and diaphoretic. Blood pressure is 80/55 mmHg, heart rate is 118 beats/min, respiratory rate is 30 breaths/min, and oxygen saturation is 88% on room air. His extremities are cold and clammy with delayed capillary refill. Jugular venous pressure is elevated, and lung auscultation reveals bilateral basal crackles. Cardiac examination demonstrates an S3 gallop, and urine output is markedly reduced. Electrocardiography shows ST-segment elevation in leads V1 to V4. Laboratory evaluation reveals elevated cardiac troponin and a serum lactate of 5.2 mmol/L. Bedside echocardiography demonstrates severe LV systolic dysfunction with an ejection fraction of approximately 25% and anterior wall hypokinesis. Right heart catheterization shows a cardiac index of 1.7 L/min/m² and a pulmonary capillary wedge pressure of 24 mmHg. Diagnosis?
Diagnosis is acute anterior STEMI complicated by cardiogenic shock,
with severe left ventricular pump failure and pulmonary congestion.
The combination of anterior STEMI, profound hypotension, cold
extremities, oliguria, elevated lactate, severe LV systolic dysfunction,
cardiac index 1.7 L/min/m², and PCWP 24 mmHg establishes a classic
congested cardiogenic shock phenotype.
1. Definition
Cardiogenic shock is a clinical syndrome of inadequate systemic
perfusion caused primarily by cardiac pump failure.
There is no single mandatory blood pressure or hemodynamic cutoff for all
patients.
Typical findings include:
1. Hypotension
1.
SBP <90 mmHg
2.
Or low MAP
3.
Or need for vasoactive support to maintain perfusion
2. Evidence
of end-organ hypoperfusion
1.
Cold extremities
2.
Delayed capillary refill
3.
Oliguria
4.
Altered mental status
5.
Elevated lactate
6.
Worsening renal or hepatic function
3. When
invasive hemodynamics are available:
1.
Cardiac index <2.2 L/min/m²
supports low-output shock
2.
Elevated PCWP supports left-sided congestion
Cardiogenic shock can occasionally occur without overt hypotension,
so systemic hypoperfusion is fundamental to the diagnosis.
2. Diagnosis in This Patient
This patient has multiple features of cardiogenic shock:
1. SBP
80 mmHg
2. Cold
and clammy extremities
3. Delayed
capillary refill
4. Marked
oliguria
5. Lactate
5.2 mmol/L
6. Cardiac
index 1.7 L/min/m²
7. PCWP
24 mmHg
8. LVEF
approximately 25%
9. Pulmonary
crackles
10. Acute
anterior STEMI
This is a cold and wet cardiogenic shock phenotype,
reflecting both hypoperfusion and congestion.
The anterior STEMI pattern in leads V1 to V4 most strongly suggests an LAD
culprit lesion.
3. Etiology
Important causes of cardiogenic shock include:
3.1 Acute Myocardial Infarction
AMI is a major cause of cardiogenic shock.
Mechanisms include:
1. Extensive
LV myocardial injury
2. RV
infarction
3. Ischemia-induced
severe ventricular dysfunction
4. Mechanical
complications
5. Malignant
arrhythmias
3.2 Acute or Acute-on-Chronic Heart Failure
Severe decompensated systolic or diastolic dysfunction can produce
cardiogenic shock even without acute MI.
3.3 Mechanical Complications of MI
These must be actively excluded:
1. Ventricular
septal rupture
2. Papillary
muscle rupture causing acute severe mitral regurgitation
3. LV
free-wall rupture with tamponade
An abrupt new murmur or sudden hemodynamic deterioration should immediately
raise concern for a mechanical complication.
3.4 Other Causes
1. Fulminant
myocarditis
2. Severe
acute valvular disease
3. Takotsubo
syndrome
4. Massive
RV infarction
5. Tachyarrhythmias
6. Severe
bradyarrhythmias
Other causes of shock that may mimic or coexist with cardiogenic shock, such
as cardiac tamponade, should also be considered. Tamponade is
conventionally classified as obstructive shock, even when it
results from post-MI free-wall rupture.
4. Pathophysiology
In AMI-related cardiogenic shock:
1. Extensive
myocardial ischemia causes reduced contractility.
2. Stroke
volume and cardiac output fall.
3. Systemic
arterial pressure declines.
4. Coronary
perfusion may decrease further.
5. Neurohormonal
activation causes:
1.
Sympathetic vasoconstriction
2.
Increased systemic vascular resistance
3.
RAAS activation
4.
Sodium and water retention
6. Increased
afterload further impairs LV ejection.
7. Elevated
LV filling pressure causes:
1.
Pulmonary venous congestion
2.
Pulmonary edema
3.
Hypoxemia
8. Progressive
tissue hypoperfusion produces:
1.
Lactic acidosis
2.
Acute kidney injury
3.
Hepatic injury
4.
Altered mental status
5.
Multiorgan failure
This creates a self-perpetuating cycle of ischemia, pump failure,
hypoperfusion, and organ dysfunction.
5. Hemodynamic Profile
Typical LV-predominant congested cardiogenic shock is characterized by:
1. Reduced
cardiac output or cardiac index
2. Elevated
LV filling pressure or PCWP
3. Increased
systemic vascular resistance may occur
4. Pulmonary
congestion
This patient has:
1. Cardiac
index 1.7 L/min/m²
2. PCWP
24 mmHg
These findings demonstrate low cardiac output with markedly elevated
left-sided filling pressure.
A complete invasive hemodynamic assessment can also help distinguish:
1. LV-predominant
shock
2. RV-predominant
shock
3. Biventricular
shock
6. SCAI Shock Classification
The SCAI classification describes cardiogenic shock severity dynamically.
Stage A: At Risk
1. At
risk for shock
2. No
current hypotension or hypoperfusion
Stage B: Beginning Shock
1. Hemodynamic
instability
2. Hypotension
or tachycardia
3. No
systemic hypoperfusion
Stage C: Classic Shock
1. Systemic
hypoperfusion
2. Often
hypotension
3. Requires
pharmacologic or mechanical support beyond simple volume correction
Typical findings include:
1. Cold
extremities
2. Oliguria
3. Lactate
≥2 mmol/L
4. Cardiac
index <2.2 L/min/m² when measured
Stage D: Deteriorating Shock
1. Stage
C physiology that fails to improve with initial therapy
2. Rising
lactate
3. Worsening
organ perfusion
4. Escalating
vasoactive or mechanical support
Stage E: Extremis
1. Actual
or impending circulatory collapse
2. Profound
refractory hypotension
3. Severe
metabolic derangement
4. Cardiac
arrest or near-arrest physiology
This patient's initial presentation is consistent with SCAI Stage C
cardiogenic shock.
Stage D should not be assigned solely because the lactate is 5.2 mmol/L.
Stage D requires evidence that the patient is deteriorating or failing
to respond after an initial therapeutic intervention.
Shock stage should be reassessed repeatedly, because
trajectory is highly prognostic.
7. Diagnostic Evaluation
7.1 ECG
The ECG identifies the ischemic territory and guides emergency reperfusion.
This patient has:
ST elevation in V1 to V4 = acute anterior STEMI, usually
involving the LAD.
7.2 Cardiac Troponin
1. Elevated
cardiac troponin indicates myocardial injury.
2. A
rise and/or fall in troponin supports acute myocardial injury.
3. In
a patient with diagnostic STEMI, reperfusion should not be delayed
while awaiting serial biomarker measurements.
7.3 Bedside Echocardiography
Urgent echocardiography evaluates:
1. LV
systolic function
2. RV
function
3. Regional
wall-motion abnormalities
4. Acute
mitral regurgitation
5. Ventricular
septal rupture
6. Pericardial
effusion or tamponade
7. Other
causes of shock
Echocardiography should not delay emergency coronary reperfusion.
7.4 Laboratory Monitoring
Important tests include:
1. Serial
lactate
2. Renal
function
3. Electrolytes
4. Liver
enzymes
5. Acid-base
status
6. Complete
blood count
7. Coagulation
profile
8. Serial
cardiac biomarkers
The trend in lactate and organ function is more useful than
a single measurement.
7.5 Invasive Hemodynamics
Pulmonary artery catheterization is not mandatory for every patient with
cardiogenic shock.
However, invasive hemodynamic monitoring can be useful in selected patients
to:
1. Define
the shock phenotype
2. Quantify
congestion
3. Assess
RV and LV function
4. Guide
vasoactive therapy
5. Select
temporary mechanical circulatory support
6. Assess
response to therapy
7. Guide
device escalation and weaning
Invasive hemodynamic assessment should not delay emergency
culprit-vessel revascularization.
8. Cardiac Power Output
Cardiac power output is calculated as:
CPO = (MAP × cardiac output) / 451
and is expressed in watts.
Low CPO is associated with adverse prognosis.
1. The
SHOCK registry identified a CPO of approximately ≤0.53 W as a
threshold associated with increased mortality.
2. A
value <0.6 W is commonly used clinically as a marker of
high-risk hemodynamic compromise.
3. CPO
should not be interpreted in isolation.
4. CPO
should not be used as the sole diagnostic criterion for cardiogenic shock.
5. CPO
should not serve as the sole trigger for mechanical circulatory support.
Cardiac output, rather than cardiac index, is required for the standard CPO
calculation.
9. Immediate Management
Management should proceed simultaneously with diagnosis.
Priorities include:
1. Immediate
coronary reperfusion
2. Restoration
of systemic perfusion
3. Treatment
of hypoxemia
4. Identification
of mechanical complications
5. Serial
reassessment of shock severity
A multidisciplinary shock team should be activated early
when available.
9.1 Oxygen and Ventilatory Support
This patient has an oxygen saturation of 88%, so
supplemental oxygen is indicated.
If pulmonary edema and respiratory distress worsen:
1. Escalate
respiratory support as needed.
2. Noninvasive
positive-pressure ventilation may benefit selected patients with cardiogenic
pulmonary edema if hemodynamics permit, but profound hypotension limits its use
because positive pressure can reduce preload and worsen hemodynamics.
3. Positive-pressure
ventilation can also reduce LV afterload, so its overall hemodynamic effect
depends on preload dependence, RV function, ventilatory pressures, and the
clinical phenotype.
4. Endotracheal
intubation may be required for severe respiratory failure, but induction and
positive-pressure ventilation can worsen shock and should be performed with
careful hemodynamic preparation.
9.2 Volume Management
This patient has:
1. Elevated
JVP
2. Pulmonary
crackles
3. PCWP
24 mmHg
Therefore:
Routine IV fluid boluses should be avoided.
He is already congested.
Volume therapy should be guided by clinical and hemodynamic assessment
rather than administered empirically.
10. Vasoactive Therapy
Vasoactive drugs should be used at the lowest effective dose for the
shortest necessary duration.
10.1 Norepinephrine
For most patients with cardiogenic shock and significant hypotension:
Norepinephrine is a reasonable initial vasoactive agent.
It can:
1. Increase
MAP
2. Improve
coronary and systemic perfusion pressure
3. Provide
modest beta-adrenergic inotropic support
No single vasoactive agent has demonstrated a definitive mortality advantage
in all cardiogenic-shock populations.
10.2 Inotropes
If cardiac output remains inadequate after achieving a reasonable perfusion
pressure, an inotrope may be added.
Options include:
1. Dobutamine
2. Milrinone
Dobutamine:
1. Increases
contractility
2. May
increase cardiac output
3. Can
cause tachyarrhythmias and hypotension
Milrinone:
1. Increases
contractility
2. Reduces
afterload
3. Can
cause significant hypotension
4. Has
a longer half-life
5. Is
renally cleared and should be used cautiously with renal dysfunction
In this profoundly hypotensive patient, milrinone would generally be
less attractive as an initial agent.
11. Definitive Treatment of AMI-Related Cardiogenic Shock
Emergency culprit-vessel revascularization is the foundational Class
I treatment with established survival benefit in AMI-related cardiogenic shock.
In selected patients with STEMI and severe or refractory cardiogenic
shock, a microaxial flow pump is also reasonable to reduce mortality.
This patient requires:
Immediate coronary angiography with primary PCI of the culprit
artery.
If PCI is not feasible because of coronary anatomy or technical
considerations, emergency CABG may be required when appropriate.
For STEMI complicated by cardiogenic shock and multivessel coronary disease:
1. Routine
immediate multivessel PCI is not recommended.
2. The
initial strategy should generally be culprit-vessel PCI only.
3. Additional
revascularization can be considered later according to anatomy, residual
ischemia, and clinical stability.
12. Antithrombotic Therapy
Treatment should follow contemporary STEMI and PCI protocols, adjusted for
bleeding risk and planned mechanical support.
Typical therapy includes:
1. Aspirin
2. A
P2Y12 inhibitor
3. Procedural
anticoagulation
Shock can impair gastrointestinal absorption of oral medications, so
antiplatelet strategy may need individualization in critically ill or
mechanically ventilated patients.
13. Mechanical Circulatory Support
Temporary mechanical circulatory support should not be used
routinely in every patient with cardiogenic shock.
Device selection should be individualized according to:
1. Shock
severity
2. LV
versus RV failure
3. Respiratory
failure
4. Mechanical
complications
5. Vascular
anatomy
6. Bleeding
risk
7. Response
to initial pharmacologic therapy
8. Institutional
expertise
13.1 Microaxial Flow Pump
A microaxial flow pump such as Impella CP provides:
1. LV
unloading
2. Increased
forward flow
3. Reduced
LV filling pressure
The DanGer-Shock trial demonstrated lower 180-day mortality
with a microaxial flow pump plus standard care compared with standard care
alone in selected patients with STEMI-related cardiogenic shock.
However:
1. Severe
adverse events were substantially more frequent.
2. Major
bleeding and limb ischemia are important risks.
3. Renal
replacement therapy was more frequent in the device group.
4. The
trial population was highly selected.
Therefore, contemporary ACS guidance considers a microaxial flow pump reasonable
in selected patients with STEMI and severe or refractory cardiogenic shock to
reduce mortality.
It should not be interpreted as mandatory therapy for every patient with
AMI-CS.
13.2 Intra-Aortic Balloon Pump
Routine IABP use in AMI-related cardiogenic shock:
Does not improve survival and is not recommended routinely.
It may still have a role in selected situations, particularly as short-term
stabilization in some patients with mechanical complications.
13.3 VA-ECMO
Routine VA-ECMO for AMI-related cardiogenic shock has not
demonstrated a survival benefit and is not recommended routinely.
VA-ECMO may still be considered as rescue support in carefully
selected patients with refractory circulatory collapse, particularly
when there is:
1. Severe
biventricular failure
2. Severe
hypoxemia
3. Cardiac
arrest
4. Potentially
reversible disease
5. A
bridge to another definitive therapy
VA-ECMO can increase LV afterload, so LV unloading may be required in
selected patients.
13.4 Mechanical Complications
When cardiogenic shock results from:
1. Ventricular
septal rupture
2. Papillary
muscle rupture
3. Other
major mechanical complications
Temporary mechanical support may be reasonable as a bridge to
definitive surgical or structural intervention.
14. Congestion Management
Once systemic perfusion pressure has been stabilized:
1. Persistent
pulmonary congestion should be treated.
2. Loop
diuretics may be used when adequate perfusion is present.
3. Diuresis
must be balanced against the risk of further reducing cardiac output.
The immediate priority in this patient remains revascularization and
restoration of perfusion.
15. Monitoring
Frequent reassessment should include:
1. Blood
pressure and MAP
2. Heart
rate and rhythm
3. Mental
status
4. Capillary
refill
5. Urine
output
6. Lactate
trend
7. Renal
and hepatic function
8. Acid-base
status
9. Oxygenation
10. Pulmonary
congestion
11. Echocardiographic
findings
12. Invasive
hemodynamics when indicated
13. Serial
SCAI shock stage
Failure of lactate to clear, worsening oliguria, progressive acidosis, or
escalating vasoactive requirements should prompt urgent reassessment and
consideration of escalation of support.
16. Complications
AMI-related cardiogenic shock may cause:
1. Multiorgan
failure
2. Acute
kidney injury
3. Ischemic
hepatitis
4. Lactic
acidosis
5. Pulmonary
edema
6. Respiratory
failure
7. Ventricular
arrhythmias
8. Bradyarrhythmias
9. Mechanical
complications of MI
10. Cardiac
arrest
11. Death
Temporary mechanical support may additionally cause:
1. Major
bleeding
2. Limb
ischemia
3. Hemolysis
4. Vascular
injury
5. Infection
6. Stroke
7. Device-related
complications
17. Prognosis
Cardiogenic shock remains a high-mortality condition.
Poor prognostic features include:
1. Advanced
age
2. Persistent
or rising lactate
3. Severe
renal dysfunction
4. Multiorgan
failure
5. Cardiac
arrest
6. Severe
biventricular failure
7. Persistent
hypotension
8. Failure
to improve with initial therapy
9. Progression
to higher SCAI shock stages
Early recognition, rapid culprit-vessel reperfusion, repeated shock staging,
and individualized hemodynamic support are critical.
18. Key Clinical Insight
Acute MI + hypotension + systemic hypoperfusion = cardiogenic shock
until proven otherwise.
For this patient:
Anterior STEMI + SBP 80 mmHg + cold extremities + oliguria + lactate
5.2 mmol/L + CI 1.7 L/min/m² + PCWP 24 mmHg = acute MI-related congested
cardiogenic shock.
The immediate priorities are:
1. Emergency
culprit-vessel PCI
2. Oxygen
for hypoxemia
3. Norepinephrine
when vasoactive support is required
4. Inotropic
support when cardiac output remains inadequate
5. Rapid
exclusion of mechanical complications
6. Serial
SCAI shock staging
7. Selective,
not routine, use of temporary mechanical circulatory support
References
1. Sinha
SS, Morrow DA, Kapur NK, Kataria R, Roswell RO. 2025 Concise Clinical Guidance:
An ACC Expert Consensus Statement on the Evaluation and Management of
Cardiogenic Shock. J Am Coll Cardiol. 2025;85(16):1618-1641.
doi:10.1016/j.jacc.2025.02.018.
2. Rao
SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for
the Management of Patients With Acute Coronary Syndromes. Circulation.
2025;151(13):e771-e862. doi:10.1161/CIR.0000000000001309.
3. Naidu
SS, Baran DA, Jentzer JC, et al. SCAI SHOCK Stage Classification Expert
Consensus Update: A Review and Incorporation of Validation Studies. J Am
Coll Cardiol. 2022;79(9):933-946. doi:10.1016/j.jacc.2022.01.018.
4. Møller JE, Engstrøm T, Jensen LO, et al. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med. 2024;390(15):1382-1393. doi:10.1056/NEJMoa2312572.
No comments:
Post a Comment